Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities

Go back to Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
(NASDAQ: GCTK) Delayed: 0.64 -0.01 (1.54%)
Previous Close $0.65    52 Week High $ 
Open $0.66    52 Week Low $ 
Day High $0.67    P/E N/A 
Day Low $0.63    EPS $ 
Volume 74,253